Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 1, 2008, Pages 10-19

  Guo, Austin M ^a,e   Sheng, Ju ^a   Scicli, Gloria M ^a   Arbab, Ali S ^a   Lehman, Norman L ^a   Edwards, Paul A ^a   Falck, John R ^b   Roman, Richard J ^c   Scicli, A Guillermo ^a,d  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYEICOSADIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; COMPLEMENTARY DNA; CYTOCHROME P450 4A1; HET 0016; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; N METHYLSULFONYL 12,12 DIBROMODODEC 11 ENAMIDE; SMALL INTERFERING RNA; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL; TUMOR VOLUME; WESTERN BLOTTING;

ALKANE 1-MONOOXYGENASE; ARACHIDONIC ACID; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOMA; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MAGNETIC RESONANCE IMAGING; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52649173364     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.140889     Document Type: Article

References (32)

1. Capdevila JH and Falck JR (2002) Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69:325-344.
2. Chen P, Guo M, Wygle D, Edwards PA, Falck JR, Roman RJ, and Scicli AG (2005) Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166:615-624.
3. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA Jr, and Schwartzman ML (2008) 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 294:H1018-H1026.
4. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, et al. (2000) Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87:60-65.
5. Gordon GR, Mulligan SJ, and MacVicar BA (2007) Astrocyte control of the cerebrovasculature. Glia 55:1214-1221.
6. Graham RA, Goodwin B, Merrihew RV, Krol WL, and Lecluyse EL (2006) Cloning, tissue expression, and regulation of beagle dog CYP4A genes. Toxicol Sci 92:356-367.
7. Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJ, and Scicli AG (2007) Activation of VEGF through ROS mediates 20-HETE-induced endothelial cell proliferation. J Pharmacol Exp Ther 321:18-27.
8. Guo M, Roman RJ, Falck JR, Edwards PA, and Scicli AG (2005a) Human U251 glioma cell proliferation is suppressed by HET0016, a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315:526-533.
9. Guo M, Roman RJ, Fenstermacher JD, Brown SL, Falck JR, Arbab AS, Edwards PA, and Scicli AG (2005b) 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by HET0016, a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317:97-108.
10. Hoelzinger DB, Demuth T, and Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99:1583-1593.
11. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, and Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622.
12. Liang CJ, Ives HE, Yang CM, and Ma YH (2008) 20-HETE inhibits the proliferation of vascular smooth muscle cells via transforming growth factor-beta. J Lipid Res 49:66-73.
13. Malumbres M and Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30:630-641.
14. Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, Dubus P, and Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118:493-504.
15. Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, and Pratt PF (2007a) Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 82:19-29.
16. Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, and Pratt PF (2007b) Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 82:19-29.
17. Medhora MM, Chen Y, Gruenloh SK, Harland D, Bodiga S, Zielonka J, Gebremedhin D, Gao Y, Falck JR, Anjaiah S, et al. (2008) 20-HETE increases superoxide production and activates NADPH oxidase in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 294:L902-L911.
18. Meloche S and Pouyssegur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26:3227-3239.
19. Metea MR and Newman EA (2006) Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 26:2862-2870.
20. Metea MR and Newman EA (2007) Signalling within the neurovascular unit in the mammalian retina. Exp Physiol 92:635-640.
21. Nguyen X, Wang MH, Reddy KM, Falck JR, and Schwartzman ML (1999) Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol Regul Integr Comp Physiol276:R1691-R1700.
22. Nilakantan V, Maenpaa C, Jia G, Roman RJ, and Park F (2008) 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294:F562-F570.
23. Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, and Cohn SL (2007) Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 13:3499-3506.
24. Pelicano H, Carney D, and Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110.
25. Reiners JJ Jr, Clift R, and Mathieu P (1999) Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor. Carcinogenesis 20:1561-1566.
26. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
27. Sacerdoti D, Gatta A, and McGiff JC (2003) Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72:51-71.
28. Sun CW, Falck JR, Harder DR, and Roman RJ (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33:414-418.
29. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, and Yodoi J (2002) Redox control of cell death. Antioxid Redox Signal 4:405-414.
30. Yoon S and Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44.
31. Yu M, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, et al. (2004) Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol 486:297-306.
32. Zhao X and Imig JD (2003) Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4:73-84.